234 related articles for article (PubMed ID: 11745184)
21. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
22. Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancer.
Tolcher AW; Gelmon KA
Semin Oncol; 1995 Aug; 22(4 Suppl 8):28-32. PubMed ID: 7638639
[TBL] [Abstract][Full Text] [Related]
23. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
Sastry J; Kellie SJ
Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
[TBL] [Abstract][Full Text] [Related]
24. Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma.
Rubin JS; Wadler S; Beitler JJ; Haynes H; Rozenblit A; McGill F; Goldberg G; Runowicz C
J Laryngol Otol; 1995 Aug; 109(8):744-7. PubMed ID: 7561498
[TBL] [Abstract][Full Text] [Related]
25. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
Culy CR; Spencer CM
Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
[TBL] [Abstract][Full Text] [Related]
27. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study.
De Souza CA; Santini G; Marino G; Nati S; Congiu AM; Vigorito AC; Damasio E
Braz J Med Biol Res; 2000 Jul; 33(7):791-8. PubMed ID: 10881054
[TBL] [Abstract][Full Text] [Related]
28. Clinical trials of WR-2721 and cis-platinum.
Glover D; Grabelsky S; Fox K; Weiler C; Cannon L; Glick J
Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1201-4. PubMed ID: 2541121
[TBL] [Abstract][Full Text] [Related]
29. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
Koukourakis MI; Yannakakis D
Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.
Wasserheit C; Frazein A; Oratz R; Sorich J; Downey A; Hochster H; Chachoua A; Wernz J; Zeleniuch-Jacquotte A; Blum R; Speyer J
J Clin Oncol; 1996 Jul; 14(7):1993-9. PubMed ID: 8683229
[TBL] [Abstract][Full Text] [Related]
31. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
[TBL] [Abstract][Full Text] [Related]
32. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
Glover D; Glick JH; Weiler C; Fox K; Guerry D
J Clin Oncol; 1987 Apr; 5(4):574-8. PubMed ID: 3031224
[TBL] [Abstract][Full Text] [Related]
33. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
34. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
Gianni L; Munzone E; Capri G; Villani F; Spreafico C; Tarenzi E; Fulfaro F; Caraceni A; Martini C; Laffranchi A
J Natl Cancer Inst; 1995 Aug; 87(15):1169-75. PubMed ID: 7674322
[TBL] [Abstract][Full Text] [Related]
37. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer.
Schiller JH
Semin Oncol; 1996 Aug; 23(4 Suppl 8):78-82. PubMed ID: 8783672
[TBL] [Abstract][Full Text] [Related]
38. Amifostine (Ethyol) as modulator of hepatic and biliary toxicity from intraarterial hepatic chemoembolization: results of a phase I study.
Fiorentini G; Giovanis P; Leoni M; De Giorgi U; Cariello A; Dazzi C; Caldeo A
Hepatogastroenterology; 2001; 48(38):313-6. PubMed ID: 11379297
[TBL] [Abstract][Full Text] [Related]
39. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
[TBL] [Abstract][Full Text] [Related]
40. Assessment of the protective effects of amifostine against cisplatin-induced toxicity.
Hussain AE; Blakley BW; Nicolas M; Balderston J
J Otolaryngol; 2003 Oct; 32(5):294-7. PubMed ID: 14974858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]